Hemant Khanna

IVERIC bio Inc., USA

Dr. Khanna is an active member of Association for Research in Vision and Ophthalmology (ARVO), American Society of Cell and Gene Therapy (ASGCT), and American Academy of Ophthalmology (AAO )and serves on review committees of ARVO and ASGCT. He is an ARVO Silver of ARVO award for exemplary contribution and dedication to ARVO.

Dr. Khanna’s research focuses on delineating the molecular mechanisms involved in retinal development and function and how their dysregulation causes disease. He utilizes genetic, cell biological and biochemical approaches to understand the mechanisms of retinal degenerative diseases and utilize the knowledge to develop new treatment paradigms. Dr. Khanna was the first to demonstrate the potential of minigenes to delay retinal degeneration in a severe form of human childhood blindness disorder.